2,163 reports of this reaction
4.4% of all CANAGLIFLOZIN reports
#3 most reported adverse reaction
OSTEOMYELITIS is the #3 most commonly reported adverse reaction for CANAGLIFLOZIN, manufactured by Janssen Pharmaceuticals, Inc.. There are 2,163 FDA adverse event reports linking CANAGLIFLOZIN to OSTEOMYELITIS. This represents approximately 4.4% of all 49,711 adverse event reports for this drug.
Patients taking CANAGLIFLOZIN who experience osteomyelitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OSTEOMYELITIS is moderately reported among CANAGLIFLOZIN users, representing a notable but not dominant share of adverse events.
In addition to osteomyelitis, the following adverse reactions have been reported for CANAGLIFLOZIN:
OSTEOMYELITIS has been reported as an adverse event in 2,163 FDA reports for CANAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
OSTEOMYELITIS accounts for approximately 4.4% of all adverse event reports for CANAGLIFLOZIN, making it one of the most commonly reported side effect.
If you experience osteomyelitis while taking CANAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.